X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.12−0.05 (-1.58%)
Close on Nov 13, 2026Market cap $309.34MP/E –Yield –
X4 Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
X4 Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was -812.0%. For fiscal 2025 it was -1336.7%, against -1400.0% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1336.7% | +63.4 |
| FY2024 | Dec 31, 2024 | -1400.0% | +595.8 |
| FY2020 | Dec 31, 2020 | -1995.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -714.0% | +1005.3 |
| Q2 FY2026 | Jun 30, 2026 | -683.0% | +860.1 |
| Q1 FY2026 | Mar 31, 2026 | -812.2% | +237.0 |
| Q4 FY2025 | Dec 31, 2025 | -1077.2% | +1303.8 |
| Q3 FY2025 | Sep 30, 2025 | -1719.3% | +4441.4 |
| Q2 FY2025 | Jun 30, 2025 | -1543.1% | −14172.4 |
| Q1 FY2025 | Mar 31, 2025 | -1049.2% | −696.5 |
| Q4 FY2024 | Dec 31, 2024 | -2381.0% | −2150.9 |
| Q3 FY2024 | Sep 30, 2024 | -6160.7% | – |
| Q2 FY2024 | Jun 30, 2024 | 12629.3% | – |
| Q1 FY2020 | Mar 31, 2020 | -352.7% | – |
| Q4 FY2018 | Dec 31, 2018 | -230.1% | – |
See a number that looks wrong?